Please login to the form below

Not currently logged in
Email:
Password:

bipolar disorder

This page shows the latest bipolar disorder news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Italy in turmoil, Pharma attacks Europe's generics move and more

Daily Brief: Italy in turmoil, Pharma attacks Europe's generics move and more

Its pipeline includes Risperidone Extended-Release Microspheres for Injection candidate (LY03004) for schizophrenia and bipolar disorder, and plans to launch in China and the US by the end of 2018, while

Latest news

  • First digital medicine approved in the US First digital medicine approved in the US

    Abilify MyCite is the latest iteration of antipsychotic blockbuster Abilify (aripiprazole) to reach the market, and is approved for the same indications as its parent products - schizophrenia, bipolar I disorder and

  • Lundbeck and Otsuka start phase III for Rexulti in bipolar Lundbeck and Otsuka start phase III for Rexulti in bipolar

    Otsuka and co-development partner Lundbeck have started two phase III trials of their atypical antipsychotic Rexulti in bipolar disorder, potentially adding a third indication for the drug. ... Abilify. Lundbeck and Otsuka are also evaluating the drug in

  • Lundbeck partners with 23andMe on first-of-its-kind study Lundbeck partners with 23andMe on first-of-its-kind study

    The US project will involve 25, 000 patients and combine data from genetics, cognitive tests and online surveys to explore how genetics is related to major depressive disorder (MDD), bipolar depression ... Anders Gersel Pedersen, executive VP, research

  • Otsuka refiles 'digital' medicine for mental illness Otsuka refiles 'digital' medicine for mental illness

    Abilify is approved to treat schizophrenia, bipolar disorder and major depressive disorder.

  • FDA knocks-back Otsuka's digital pill plans FDA knocks-back Otsuka's digital pill plans

    Otsuka had submitted the device for approval to measure medication adherence to Abilify (aripiprazole) in patients with schizophrenia, as an acute treatment of manic and mixed episodes associated with bipolar I ... disorder and as an adjunctive treatment

More from news
Approximately 7 fully matching, plus 80 partially matching documents found.

Latest Intelligence

  • Drug pricing in Ireland Drug pricing in Ireland

    As such, patients with coronary syndromes, multiple sclerosis, bipolar disorder and Hepatitis C were being denied access to effective treatments, while treatments for other diseases were also subject to restrictions.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics